文献速递淋巴瘤

IRF8是弥漫性大B细胞淋巴瘤中CD37表达的转录激活因子

IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2022-01-01

本研究探讨弥漫性大B细胞淋巴瘤(DLBCL)中CD37差异表达的分子机制。CD37阳性与阴性原发DLBCL样本的CD37启动子区DNA甲基化无差异,但CD37阴性DLBCL细胞特异性缺乏CD37启动子活性。通过无偏定量蛋白质组学鉴定转录因子IRF8在CD37阳性较CD37阴性DLBCL核提取物中显著高表达,DNA pulldown联合质谱和靶向ChIP证实IRF8直接结合CD37启动子区;IRF8过表达增强CD37蛋白表达,而CRISPR/Cas9敲除IRF8降低DLBCL细胞系CD37水平。206例原发DLBCL免疫组化分析显示IRF8表达与可检测CD37水平显著相关。

要点

  • CD37阳性与阴性原发DLBCL的CD37启动子区DNA甲基化无差异。
  • CD37阴性DLBCL细胞特异性缺乏CD37启动子活性。
  • IRF8在CD37阳性较CD37阴性DLBCL核提取物中显著高表达并直接结合CD37启动子。

核心结论

  • 本研究为人类DLBCL中CD37差异表达的分子机制提供新见解,并揭示IRF8是B细胞淋巴瘤中CD37的转录调控因子。

研究设计与样本

  • 研究在人DLBCL中从(表观)遗传和转录水平探讨CD37基因调控。
  • 免疫组化分析纳入大队列原发DLBCL(n=206)。

主要发现

  • CD37阳性与CD37阴性原发DLBCL患者样本的CD37启动子区DNA甲基化无差异。
  • CD37阴性DLBCL细胞特异性缺乏CD37启动子活性。
  • 无偏定量蛋白质组学显示转录因子IRF8在CD37阳性较CD37阴性DLBCL核提取物中显著高表达。
  • DNA pulldown联合质谱和靶向染色质免疫沉淀证实IRF8直接结合CD37启动子区。
  • IRF8过表达增强CD37蛋白表达,CRISPR/Cas9敲除IRF8降低DLBCL细胞系CD37水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) represents the most common form of non-Hodgkin lymphoma (NHL) that is still incurable in a large fraction of patients. Tetraspanin CD37 is highly expressed on mature B lymphocytes, and multiple CD37-targeting therapies are under clinical development for NHL. However, CD37 expression is nondetectable in ∼50% of DLBCL patients, which correlates with inferior treatment outcome, but the underlying mechanisms for differential CD37 expression in DLBCL are still unknown. Here, we investigated the regulation of the CD37 gene in human DLBCL at the (epi-)genetic and transcriptional level. No differences were observed in DNA methylation within the CD37 promoter region between CD37-positive and CD37-negative primary DLBCL patient samples. On the contrary, CD37-negative DLBCL cells specifically lacked CD37 promoter activity, suggesting differential regulation of CD37 gene expression. Using an unbiased quantitative proteomic approach, we identified transcription factor IRF8 to be significantly higher expressed in nuclear extracts of CD37-positive as compared with CD37-negative DLBCL. Direct binding of IRF8 to the CD37 promoter region was confirmed by DNA pulldown assay combined with mass spectrometry and targeted chromatin immunoprecipitation (ChIP). Functional analysis indicated that IRF8 overexpression enhanced CD37 protein expression, while CRISPR/Cas9 knockout of IRF8 decreased CD37 levels in DLBCL cell lines. Immunohistochemical analysis in a large cohort of primary DLBCL (n = 206) revealed a significant correlation of IRF8 expression with detectable CD37 levels. Together, this study provides new insight into the molecular mechanisms underlying differential CD37 expression in human DLBCL and reveals IRF8 as a transcriptional regulator of CD37 in B-cell lymphoma.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Elfrink S, Ter Beest M, Janssen L, et al. IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma. Blood Adv. 2022. PMID: 35086136. doi:10.1182/bloodadvances.2021004366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。